RxDoctor Payments Data

Elias Kolettis, DO

Internal Medicine · Clearwater, FLNPI 1346245891

Payments from drug & device makers

$4,294in general payments, 2019–2025

Across 183 payments — averaging $23.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$956
  • AbbVie$871
  • Lilly USA, LLC$474
  • GSK$278
  • Pfizer$194
  • plus $412 from 12 others

What the payments were for

  • Food & beverage$4,294100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,294 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$90,266
Medicare patients
250
Services billed
727

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin102$114,606
EliquisApixaban86$72,964
FarxigaDapagliflozin Propanediol52$71,849
MounjaroTirzepatide53$55,528
TrulicityDulaglutide39$51,005
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$38,031
OzempicSemaglutide26$25,142
Breo ElliptaFluticasone/Vilanterol30$18,732
MyrbetriqMirabegron21$15,312
JanuviaSitagliptin Phosphate11$11,714
Repatha SureclickEvolocumab11$10,847
Dexlansoprazole DrDexlansoprazole16$6,918
SymbicortBudesonide/Formoterol Fumarate11$3,647
Atorvastatin Calcium359$2,788
SynthroidLevothyroxine Sodium20$2,725

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$90$114,606102 claims
Lilly USA, LLCMounjaro, Trulicity$474$106,53392 claims
AstraZenecaFarxiga, Symbicort$1,109$75,49763 claims
PfizerEliquis$194$72,96486 claims
GSKTrelegy Ellipta, Breo Ellipta$278$56,76371 claims
Novo NordiskOzempic$956$25,14226 claims
Astellas Pharma US IncMyrbetriq$63$15,31221 claims
MerckJanuvia$12$11,71411 claims
AbbVieSynthroid$871$2,72520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Clearwater

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →